The rotavirus vaccines market focuses on vaccines that protect infants and young children from rotavirus infection, a leading cause of severe diarrhea and dehydration worldwide. Growth is driven by the high global burden of rotavirus-related illnesses, inclusion of these vaccines in national immunization programs, and strong support from organizations such as the WHO and UNICEF. Widely used vaccine types include live attenuated oral vaccines, which are administered in multiple doses during early infancy. North America holds a significant share due to established vaccination schedules and high coverage rates, while Asia-Pacific and Africa are experiencing rapid growth as governments and global health initiatives expand access to routine immunization. Key challenges include maintaining cold-chain logistics in low-income regions and addressing vaccine hesitancy in certain populations.
The global rotavirus vaccines market size was valued at USD 5.19 billion in 2024 and is projected to grow from USD 5.22 billion in 2025 to USD 10.21 billion by 2032, exhibiting a CAGR of 10.1% during the forecast period. North America dominated the rotavirus vaccines market with a 38.53% share in 2024, supported by strong immunization programs, rising awareness of pediatric infectious diseases, and robust healthcare infrastructure.
In January 2024, SINOVAC received approval from China’s National Medical Products Administration (NMPA) for the clinical trial of its reassortant rotavirus vaccine. This regulatory milestone adds to the dynamic pipeline landscape of rotavirus vaccine development.